Vertex have been trialling a combination small molecular therapy for DeltaF508 using both VX-770 (KALYDECO) and VX-809. Part 1 of the Phase 2 study has been completed with no major safety issues and some results which range between equivocal and potentially
promising. Patients are being enrolled in the USA for Part 2 of the Phase 2 study.
More details can be found here
And do not forget that it is hoped that the full Phase 2 multi-dose trial for the proposed gene therapy treatment will start at some point this year. Unlike the small molecule treatments being explored by Vertex, it is hoped that the gene therapy will be effective regardless of which mutation(s) a patient carries.